2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapy
2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelines